Investor Overview

• Arena is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs.
• Our internally discovered and developed drug, BELVIQ® (lorcaserin HCl), is approved by the US Food and Drug Administration and now available in the United States. Following are links to certain additional information:
  
   
  
  • Press Release
  • www.belviq.com
  • Full Prescribing Information
   

• We have granted exclusive marketing and distribution rights for BELVIQ to Eisai Inc. and Eisai Co., Ltd., for most territories worldwide; to Ildong Pharmaceutical Co., Ltd., for South Korea; to CY Biotech Company Limited for Taiwan; and to Teva Pharmaceutical Industries Ltd.’s local Israeli subsidiary, Abic Marketing Limited, for Israel.

• We are exploring BELVIQ’s therapeutic potential in combination with other drugs and for other indications.

• We are utilizing our validated discovery and development approach to selectively advance our pipeline of internally discovered, oral drug candidates.

Frequently Asked Questions